YTHDF1 gene polymorphisms and neuroblastoma susceptibility in Chinese children: an eight-center case-control study

• Published in: Journal of Cancer Vol. 12; no. 8; pp. 2465 - 2471
• Main Authors: Liu, Jiabin, Cheng, Jiwen, Li, Li, Li, Yong, Zhou, Haixia, Zhang, Jiao, Li, Suhong, Xia, Huimin, He, Jing, Yang, Zhonghua
• Format: Journal Article
• Language: English
• Published: Australia Ivyspring International Publisher Pty Ltd 01.01.2021; Ivyspring International Publisher
• Subjects: Age; Bladder cancer; Cancer therapies; DNA methylation; Gene expression; Genotype & phenotype; Medical prognosis; Metastasis; Neuroblastoma; Pediatrics; Regression analysis; Research Paper; Risk factors; Transcription factors; Tumorigenesis; Tumors; YTHDF1; m6A modification; polymorphism; neuroblastoma susceptibility
• ISSN: 1837-9664; 1837-9664
• DOI: 10.7150/jca.54496

Neuroblastoma is one of the most common life-threatening extracranial tumors that mainly occurs in children, and its genetic etiology remains largely obscure. RNA m6A modification has been thought to play a key role in cancer progression. is the critical downstream gene by which RNA m6A modification exerts its functions. Single nucleotide polymorphisms in the gene may affect its expression and biological activity, thereby leading to abnormalities in the regulation of downstream m6A-modified RNA and eventually promoting the initiation and development of tumors. Here, we attempted to evaluate the contributions of two polymorphisms (rs6011668 C>T and rs6090311 A>G) in the gene to neuroblastoma susceptibility in 898 cases and 1734 controls that originated in China. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated in the logistic regression models to evaluate the associations between selected polymorphisms and neuroblastoma risk. Overall, either in a single locus or combination analysis, no significant association with neuroblastoma risk was found for either of the two selected polymorphisms. However, the stratified analysis showed that rs6090311AG/GG genotypes significantly reduced the neuroblastoma risk in males (adjusted OR=0.77, 95% CI=0.62-0.96, =0.018). Moreover, we found that subjects with 2 protective genotypes had a lower tumor risk in males than in those with 0-1 protective genotypes (adjusted OR=0.77, 95% CI=0.62-0.96, =0.018). In summary, our study indicates that gene polymorphisms may weakly contribute to neuroblastoma susceptibility. Our findings should be further verified by well-designed studies with larger sample sizes.